From b7836e02f73ab8c7cdf5b146bdbc496fe8475853 Mon Sep 17 00:00:00 2001 From: borja Date: Tue, 4 Feb 2025 13:35:11 +0100 Subject: [PATCH] Auto saved by Logseq --- journals/2025_02_04.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/journals/2025_02_04.md b/journals/2025_02_04.md index 3a51f741..651b866e 100644 --- a/journals/2025_02_04.md +++ b/journals/2025_02_04.md @@ -7,7 +7,7 @@ En 2017, Mundo Sano se alió con EDCTP para financiar conjuntamente ensayos clínicos de herramientas innovadoras destinadas a enfermedades infecciosas desatendidas. De esta iniciativa surgieron los proyectos STOP 1 y 2, que llevaron a cabo el ensayo clínico (fase 2/3) que ha sustentado el dossier enviado a EMA. También son la base del proyecto STOP2030, del que forma parte Mundo Sano y que busca generar nuevas evidencias sobre seguridad en grandes poblaciones, coste eficiencia y aceptabilidad. - Inglés - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for the fixed-dose combination (FDC) of albendazole and ivermectin for the treatment of soil-transmitted helminths (STH) and lymphatic filariasis (LF). This marks a significant milestone for this pharmacological tool and brings it closer to its mass adoption by endemic countries. - - The FDC combines two antiparasitic drugs, albendazole and ivermectin, + - The FDC combines two antiparasitic drugs, albendazole and ivermectin, in a fixed-dose tablet that deliver multiple improvements at once. It can control more parasite species than the current standard why - - -